Aurora Spine Launches New Biologics Portfolio

Executive Summary

• Aurora Spine announced the creation of Aurora Biologics, a new division delivering allograft biologic products for spinal fusion.
• The launch adds three flagship biologic offerings—TURBO FUSE™ Fiber Putty, OSTEO GRAFT™ DBM Putty, and OSTEO BRIDGE™ Sponge Strips—designed to work with Aurora’s existing minimally invasive implant portfolio.
• Management projects the new biologics line will generate >30 % revenue growth over prior biologic offerings, enhancing margins and creating a “new profit engine” for the company.

Key Details

• Division Formation: Aurora Biologics established as an integrated platform to combine mechanical fusion systems (ZIP™, Hydra A.E.R.O.™, DEXA™, SiLO™) with regenerative biologic solutions.
• Product Suite:
• TURBO FUSE™ Fiber Putty – dematerialized bone fibers for increased surface area and cellular attachment.
• OSTEO GRAFT™ DBM Putty – demineralized cortical bone graft, moldable, carrier‑free.
• OSTEO BRIDGE™ Sponge Strips – sponge‑like, conformable bone substitute for void filling and structural regeneration.
• All products are 100 % allograft bone, free of synthetic carriers, providing osteoconductive and osteoinductive properties.
• Strategic Rationale: Provides a seamless, fully integrated portfolio from implantation to healing phase, aiming to improve patient outcomes, surgical efficiency, and long‑term fusion integrity.
• Financial Outlook (Management Commentary): Anticipated >30 % increase in revenue from biologics versus prior offerings; expected margin uplift and a new profit driver for Aurora Spine.
• Executive Comments:
• Mathew Goldstone, Chief Commercial Officer – emphasizes completion of an integrated portfolio covering both mechanical and biological aspects of fusion.
• Trent J. Northcutt, President & CEO – highlights the biologics line as a strong growth catalyst and margin enhancer.

Notable Quotes

• “Aurora Biologics completes our strategy of providing customers with a seamless, fully integrated portfolio.” – Mathew Goldstone, Chief Commercial Officer
• “We anticipate more than a 30 percent increase over prior biologic offerings—driving stronger margins and creating a powerful new profit engine for Aurora Spine.” – Trent J. Northcutt, President & CEO